Royal Bank of Canada Reiterates Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS)

NewAmsterdam Pharma (NASDAQ:NAMS)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank of Canada in a research report issued on Thursday, Benzinga reports. They presently have a $31.00 target price on the stock. Royal Bank of Canada’s target price points to a potential upside of 90.07% from the company’s current price.

Several other research analysts also recently issued reports on NAMS. TD Cowen started coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, May 15th. They set a “buy” rating on the stock. Needham & Company LLC started coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, August 28th. They set a “buy” rating and a $36.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $33.80.

NewAmsterdam Pharma Trading Up 1.8 %

Shares of NASDAQ NAMS traded up $0.29 during mid-day trading on Thursday, reaching $16.31. The company had a trading volume of 30,076 shares, compared to its average volume of 255,848. The firm has a 50 day simple moving average of $17.89 and a two-hundred day simple moving average of $19.76. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $2.20 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -2.06 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Michael H. Davidson bought 5,000 shares of the stock in a transaction dated Thursday, June 20th. The shares were acquired at an average price of $17.26 per share, with a total value of $86,300.00. Following the completion of the acquisition, the chief executive officer now directly owns 204,784 shares in the company, valued at $3,534,571.84. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the second quarter worth about $38,000. Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma during the second quarter worth about $194,000. Wolverine Asset Management LLC raised its position in NewAmsterdam Pharma by 117.7% during the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after acquiring an additional 8,394 shares during the last quarter. Sei Investments Co. raised its position in shares of NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after buying an additional 8,087 shares during the last quarter. Finally, Yarbrough Capital LLC purchased a new position in shares of NewAmsterdam Pharma during the first quarter valued at approximately $567,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.